MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
417.84
+1.66
+0.40%
After Hours: 418.50 +0.66 +0.16% 18:13 08/13 EDT
OPEN
419.92
PREV CLOSE
416.18
HIGH
420.26
LOW
415.78
VOLUME
2.78M
TURNOVER
--
52 WEEK HIGH
421.79
52 WEEK LOW
264.02
MARKET CAP
225.90B
P/E (TTM)
25.95
1D
5D
1M
3M
1Y
5Y
1D
Pharma companies sour on Swiss drug applications amid Trump’s MFN policy
Seeking Alpha · 6h ago
Notable ETF Inflow Detected - XLV, UNH, MRK, AMGN
NASDAQ · 7h ago
Sino Biopharmaceutical Stock Slips 1.1% in Hong Kong, Underperforms Competitors
Dow Jones · 13h ago
Is Amgen (AMGN) Fully Valued On Strong Q2 Results And Raised 2026 Guidance?
Simply Wall St · 16h ago
Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'
Benzinga · 19h ago
23 dividend safety stocks beating the S&P 500 this year
Seeking Alpha · 1d ago
SCHD, RDTL: Big ETF Inflows
NASDAQ · 1d ago
SCHD vs. VYMI vs. VIG: Which Is the Best Dividend ETF for Passive Income Investors?
TipRanks · 1d ago
More
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.